Caveolin-1 regulates chemokine receptor 5-mediated contribution of bone marrow-derived cells to dermal fibrosis

Frontiers in Pharmacology

Volumn 5 JUN, Issue , 2014, Pages

  Lee, Rebecca ^a   Perry, Beth ^a   Heywood, Jonathan ^a   Reese, Charles ^a   Bonner, Michael ^a   Hatfield, Corey M ^a   Silver, Richard M ^a   Visconti, Richard P ^a   Hoffman, Stanley ^a   Tourkina, Elena ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Adipocyte; Bleomycin; Fibrocyte; Lipodystrophy; Migration; Monocyte; Scleroderma

Indexed keywords

BLEOMYCIN; CAVEOLIN 1; CAVEOLIN 1 SCAFFOLDING DOMAIN PEPTIDE; CHEMOKINE RECEPTOR CCR5; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; SCAFFOLD PROTEIN; UNCLASSIFIED DRUG;

ADIPOCYTE; ADIPOSE DERIVED STEM CELL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOACCUMULATION; BONE MARROW CELL; CELL DIFFERENTIATION; CELL MIGRATION; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DERMIS; FIBROBLAST; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; LEUKOCYTE; LIGAND BINDING; LIPODYSTROPHY; MALE; MONOCYTE; MOUSE; MOUSE MODEL; NONHUMAN; PROTEIN DETERMINATION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; SCLERODERMA; SKIN FIBROSIS; SKINFOLD THICKNESS; TISSUE DISTRIBUTION;

EID: 84904737300     PISSN: None     EISSN: 16639812     Source Type: Journal    
DOI: 10.3389/fphar.2014.00140     Document Type: Article

References (43)

1. Abraham, D. J., and Varga, J. (2005). Scleroderma: from cell and molecular mechanisms to disease models. Trends Immunol. 26, 587-595. doi: 10.1016/j.it.2005.09.004.
2. Altman, R. D., Medsger, T. A. Jr., Bloch, D. A., and Michel, B. A. (1991). Predictors of survival in systemic sclerosis (scleroderma). Arthritis Rheum. 34, 403-413. doi: 10.1002/art.1780340405.
3. Arakawa, H., Jinnin, M., Muchemwa, F. C., Makino, T., Kajihara, I., Makino, K., et al. (2011). Adiponectin expression is decreased in the involved skin and sera of diffuse cutaneous scleroderma patients. Exp. Dermatol. 20, 764-766. doi: 10.1111/j.1600-0625.2011.01310.x.
4. Bandinelli, F., Del Rosso, A., Gabrielli, A., Giacomelli, R., Bartoli, F., Guiducci, S., et al. (2012). CCL2, CCL3 and CCL5 chemokines in systemic sclerosis: the correlation with SSc clinical features and the effect of prostaglandin E1 treatment. Clin. Exp. Rheumatol. 30, S44-S49.
5. Berres, M. L., Koenen, R. R., Rueland, A., Zaldivar, M. M., Heinrichs, D., Sahin, H., et al. (2010). Antagonism of the chemokine Ccl5 ameliorates experimental liver fibrosis in mice. J. Clin. Invest. 120, 4129-4140. doi: 10.1172/JCI41732.
6. Boin, F., De Fanis, U., Bartlett, S. J., Wigley, F. M., Rosen, A., and Casolaro, V. (2008). T cell polarization identifies distinct clinical phenotypes in scleroderma lung disease. Arthritis Rheum. 58, 1165-1174. doi: 10.1002/art.23406.
7. Bolster, M. B., Ludwicka, A., Sutherland, S. E., Strange, C., and Silver, R. M. (1997). Cytokine concentrations in bronchoalveolar lavage fluid of patients with systemic sclerosis. Arthritis Rheum. 40, 743-751. doi: 10.1002/art.1780400422.
8. Capelli, A., Di Stefano, A., Gnemmi, I., and Donner, C. F. (2005). CCR5 expression and CC chemokine levels in idiopathic pulmonary fibrosis. Eur. Respir. J. 25, 701-707. doi: 10.1183/09031936.05.00082604.
9. Chesney, J., Metz, C., Stavitsky, A. B., Bacher, M., and Bucala, R. (1998). Regulated production of type I collagen and inflammatory cytokines by peripheral blood fibrocytes. J. Immunol. 160, 419-425.
10. Codullo, V., Baldwin, H. M., Singh, M. D., Fraser, A. R., Wilson, C., Gilmour, A., et al. (2011). An investigation of the inflammatory cytokine and chemokine network in systemic sclerosis. Ann. Rheum. Dis. 70, 1115-1121. doi: 10.1136/ard.2010.137349.
11. Del Galdo, F., Sotgia, F., De Almeida, C. J., Jasmin, J. F., Musick, M., Lisanti, M. P., et al. (2008). Decreased expression of caveolin 1 in patients with systemic sclerosis: crucial role in the pathogenesis of tissue fibrosis. Arthritis Rheum. 58, 2854-2865. doi: 10.1002/art.23791.
12. Di Guglielmo, G. M., Le Roy, C., Goodfellow, A. F., and Wrana, J. L. (2003). Distinct endocytic pathways regulate TGF-beta receptor signalling and turnover. Nat. Cell Biol. 5, 410-421. doi: 10.1038/ncb975.
13. Fang, F., Liu, L., Yang, Y., Tamaki, Z., Wei, J., Marangoni, R. G., et al. (2012). The adipokine adiponectin has potent anti-fibrotic effects mediated via adenosine monophosphate-activated protein kinase: novel target for fibrosis therapy. Arthritis Res. Ther. 14, R229. doi: 10.1186/ar4070.
14. Gambichler, T., Genc, Z., Skrygan, M., Scola, N., Tigges, C., Terras, S., et al. (2012). Cytokine and chemokine ligand expression in cutaneous lupus erythematosus. Eur. J. Dermatol. 22, 319-323. doi: 10.1684/ejd.2012.1725.
15. Gambichler, T., Skrygan, M., Labanski, A. A., Kolios, A. G., Altmeyer, P., and Kreuter, A. (2011). Significantly increased CCL5/RANTES and CCR7 mRNA levels in localized scleroderma. Regul. Pept. 170, 4-6. doi: 10.1016/j.regpep.2011.05.003.
16. Hartlapp, I., Abe, R., Saeed, R. W., Peng, T., Voelter, W., Bucala, R., et al. (2001). Fibrocytes induce an angiogenic phenotype in cultured endothelial cells and promote angiogenesis in vivo. FASEB J. 15, 2215-2224. doi: 10.1096/fj.01-0049com.
17. Hasegawa, M., Sato, S., and Takehara, K. (1999). Augmented production of chemokines (monocyte chemotactic protein-1 (MCP-1), macrophage inflammatory protein-1alpha (MIP-1alpha) and MIP-1beta) in patients with systemic sclerosis: MCP-1 and MIP-1alpha may be involved in the development of pulmonary fibrosis. Clin. Exp. Immunol. 117, 159-165. doi: 10.1046/j.1365-2249.1999.00929.x.
18. Hung, C., Linn, G., Chow, Y. H., Kobayashi, A., Mittelsteadt, K., Altemeier, W. A., et al. (2013). Role of lung pericytes and resident fibroblasts in the pathogenesis of pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 188, 820-830. doi: 10.1164/rccm.201212-2297OC.
19. Ishida, Y., Kimura, A., Kondo, T., Hayashi, T., Ueno, M., Takakura, N., et al. (2007). Essential roles of the CC chemokine ligand 3-CC chemokine receptor 5 axis in bleomycin-induced pulmonary fibrosis through regulation of macrophage and fibrocyte infiltration. Am. J. Pathol. 170, 843-854. doi: 10.2353/ajpath.2007.051213.
20. Lakota, K., Wei, J., Carns, M., Hinchcliff, M., Lee, J., Whitfield, M. L., et al. (2012). Levels of adiponectin, a marker for PPAR-gamma activity, correlate with skin fibrosis in systemic sclerosis: potential utility as biomarker? Arthritis Res. Ther. 14, R102. doi: 10.1186/ar3827.
21. Lee, R., Reese, C., Bonner, M., Tourkina, E., Hajdu, Z., Riemer, E. C., et al. (2014). Bleomycin delivery by osmotic mini-pump: similarity to human scleroderma interstitial lung disease. Am. J. Physiol. Lung Cell. Mol. Physiol. 306, L736-L748. doi: 10.1152/ajplung.00210.2013.
22. LeRoy, E. C., Black, C., Fleishmajer, R., Jablonska, S., Krieg, T., Medsger, T. A. Jr., et al. (1988). Scleroderma (systemic sclerosis): classification, subsets, and pathogenesis. J. Rheumatol. 15, 202-205.
23. Li, S., Okamoto, T., Chun, M., Sargiacomo, M., Casanova, J. E., Hansen, S. H., et al. (1995). Evidence for a regulated interaction between heterotrimeric G proteins and caveolin. J. Biol. Chem. 270, 15693-15701. doi: 10.1074/jbc.270.26.15693.
24. Liu, R., Paxton, W. A., Choe, S., Ceradini, D., Martin, S. R., Horuk, R., et al. (1996). Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell 86, 367-377. doi: 10.1016/S0092-8674(00)80110-5.
25. Marangoni, R., Wei, J., Hinchcliff, M., Fang, F., Tourtellotte, W., and Varga, J. (2012). Aberrant Adipogenesis in the Pathogenesis of Scleroderma. Arthritis Rheum. 64, S341-S342. doi: 10.1002/art.38520.
26. Mizuno, H. (2010). Adipose-derived stem and stromal cells for cell-based therapy: current status of preclinical studies and clinical trials. Curr. Opin. Mol. Ther. 12, 442-449.
27. Nellen, A., Heinrichs, D., Berres, M. L., Sahin, H., Schmitz, P., Proudfoot, A. E., et al. (2012). Interference with oligomerization and glycosaminoglycan binding of the chemokine CCL5 improves experimental liver injury. PLoS ONE 7:e36614. doi: 10.1371/journal.pone.0036614.
28. Oppermann, M. (2004). Chemokine receptor CCR5: insight into structure, function, and regulation. Cell. Signal. 16, 1201-1210. doi: 10.1016/j.cellsig.2004.04.007.
29. Razani, B., Combs, T. P., Wang, X. B., Frank, P. G., Park, D. S., Russell, R. G., et al. (2002). Caveolin-1-deficient mice are lean, resistant to diet-induced obesity, and show hypertriglyceridemia with adipocyte abnormalities. J. Biol. Chem. 277, 8635-8647. doi: 10.1074/jbc.M110970200.
30. Rosen, E. D., and Spiegelman, B. M. (2014). What we talk about when we talk about fat. Cell 156, 20-44. doi: 10.1016/j.cell.2013.12.012.
31. Samson, M., Libert, F., Doranz, B. J., Rucker, J., Liesnard, C., Farber, C. M., et al. (1996). Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature 382, 722-725. doi: 10.1038/382722a0.
32. Seki, E., De Minicis, S., Gwak, G. Y., Kluwe, J., Inokuchi, S., Bursill, C. A., et al. (2009). CCR1 and CCR5 promote hepatic fibrosis in mice. J. Clin. Invest. 119, 1858-1870.
33. Silver, R. M. (1995). Interstitial lung disease of systemic sclerosis. Int. Rev. Immunol. 12, 281-291. doi: 10.3109/08830189509056718.
34. Steffens, C. M., and Hope, T. J. (2004). Mobility of the human immunodeficiency virus (HIV) receptor CD4 and coreceptor CCR5 in living cells: implications for HIV fusion and entry events. J. Virol. 78, 9573-9578. doi: 10.1128/JVI.78.17.9573-9578.2004.
35. Stock, M. K., Hammerich, L., Do, O. N., Berres, M. L., Alsamman, M., Heinrichs, D., et al. (2013). Met-CCL5 modifies monocyte subpopulations during liver fibrosis regression. Int. J. Clin. Exp. Pathol. 6, 678-685.
36. Subcommittee. (1980). Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum. 23, 581-590.
37. Sun, K., Tordjman, J., Clement, K., and Scherer, P. E. (2013). Fibrosis and adipose tissue dysfunction. Cell Metab. 18, 470-477. doi: 10.1016/j.cmet.2013.06.016.
38. Tourkina, E., Bonner, M., Oates, J., Hofbauer, A., Richard, M., Znoyko, S., et al. (2011). Altered monocyte and fibrocyte phenotype and function in scleroderma interstitial lung disease: reversal by caveolin-1 scaffolding domain peptide. Fibrogenesis Tissue Repair. 4:15. doi: 10.1186/1755-1536-4-15.
39. Tourkina, E., Gooz, P., Pannu, J., Bonner, M., Scholz, D., Hacker, S., et al. (2005). Opposing effects of protein kinase Calpha and protein kinase Cepsilon on collagen expression by human lung fibroblasts are mediated via MEK/ERK and caveolin-1 signaling. J. Biol. Chem. 280, 13879-13887. doi: 10.1074/jbc.M412551200.
40. Tourkina, E., Richard, M., Gooz, P., Bonner, M., Pannu, J., Harley, R., et al. (2008). Antifibrotic properties of caveolin-1 scaffolding domain in vitro and in vivo. Am. J. Physiol. Lung Cell. Mol. Physiol. 294, L843-L861. doi: 10.1152/ajplung.00295.2007.
41. Tourkina, E., Richard, M., Oates, J., Hofbauer, A., Bonner, M., Gooz, P., et al. (2010). Caveolin-1 regulates leucocyte behaviour in fibrotic lung disease. Ann. Rheum. Dis. 69, 1220-1226. doi: 10.1136/ard.2009.117580.
42. Tyndall, A. (2011). Successes and failures of stem cell transplantation in autoimmune diseases. Hematol. Am. Soc. Hematol. Educ. Prog. 2011, 280-284. doi: 10.1182/asheducation-2011.1.280.
43. Wang, X. M., Zhang, Y., Kim, H. P., Zhou, Z., Feghali-Bostwick, C. A., Liu, F., et al. (2006). Caveolin-1: a critical regulator of lung fibrosis in idiopathic pulmonary fibrosis. J. Exp. Med. 203, 2895-2906. doi: 10.1084/jem.20061536